Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 9:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,781 matching trials from the live ClinicalTrials.gov search.
Conditions
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
PU-H71, Ruxolitinib
Drug
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
New Haven, Connecticut • New Orleans, Louisiana • Ann Arbor, Michigan + 7 more
Conditions
Breast Cancer
Interventions
Ribociclib, Everolimus, Exemestane
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
25
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Los Angeles, California + 20 more
Conditions
Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
Interventions
VS-6766/avutometinib, Cetuximab, Pill Diary
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Basal Cell Carcinoma
Interventions
Nivolumab, Relatlimab plus Nivolumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Irvine, California • La Jolla, California • San Francisco, California
Conditions
Diabetes
Interventions
Application Validation
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Head and Neck Cancer
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Healthy Volunteers
Interventions
AZD2373 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Brooklyn, Maryland
Conditions
ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum, Generalized Arterial Calcification of Infancy
Interventions
INZ-701
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
18 Years to 69 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Eatontown, New Jersey
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Treprostinil sodium for inhalation
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
35 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more
Conditions
Kidney Disease
Interventions
darTreg infusion
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Conditions
Multiple Myeloma
Interventions
PCI-32765, Dexamethasone
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
11
States / cities
La Jolla, California • Baltimore, Maryland • Boston, Massachusetts + 7 more
Conditions
Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
Durvalumab, Danvatirsen, Oleclumab, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Iowa City, Iowa • Pittsburgh, Pennsylvania • Nashville, Tennessee
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Glioblastoma Multiforme, Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Renal Cell Carcinoma
Interventions
DSP-7888 Dosing Emulsion
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
Denver, Colorado • Atlanta, Georgia • Lafayette, Indiana + 5 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1a Study of PMN310 In Healthy Volunteers

NCT06105528
Conditions
Healthy Participants
Interventions
PMN310, Placebo
Drug
Lead sponsor
ProMis Neurosciences, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Miami, Florida • Columbus, Ohio
Conditions
Diabetic Macular Edema
Interventions
CU06-1004, Single dose, CU06-1004, Multiple doses, Placebo
Drug
Lead sponsor
Curacle Co., Ltd.
Industry
Eligibility
19 Years to 55 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Brain Metastases
Interventions
Temozolomide, Valproic Acid, Whole Brain Radiation Therapy
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Resmetirom, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 12 more
Conditions
Nasal Polyps, Chronic Rhinosinusitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
Conditions
Healthy
Interventions
amikacin/fosfomycin
Drug
Lead sponsor
Cardeas Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Myelodysplastic Syndromes
Interventions
Lenalidomide, Luspatercept
Drug
Lead sponsor
Mikkael Sekeres, MD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 2 more
Conditions
Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma
Interventions
Microdevices, Standard of care therapy, Standard of care systemic therapy
Device · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer, Metastatic Pancreatic Cancer, Metastatic Solid Tumors
Interventions
MC001
Biological
Lead sponsor
Medicovestor, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Syracuse, New York • Huntersville, North Carolina • San Antonio, Texas + 1 more
Conditions
Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
Interventions
Not listed
Lead sponsor
Biological Dynamics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Diego, California
Conditions
Neuropsychiatric Systemic Lupus Erythematosus
Interventions
Magnetic Resonance Angiography (MRA), Magnetic resonance imaging, MRA, diffusion Imaging, perfusion imaging.
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan